MARKET NEWS

Aptinyx Presents Data Demonstrating Positive Activity on Cognitive Performance & Biomarkers in a Preclinical Model
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial
MyoKardia Begins Dosing in Phase 1 Clinical Study
Outlook Therapeutics Completes Patient Enrollment for Phase 3 Clinical Trial
Altimmune Announces $3.7 Million in Additional BARDA Funding
Ivy Brain Tumor Center & Salarius Pharmaceuticals Launch Collaborative Partnership 

  FEATURED EDITORIAL

  COMPANY PROFILE

Founded in 1977, JRF Global is one of the oldest (40+ years) and most respected non-clinical Contract Research Organization in Asia. JRF’s capabilities spanning from Discovery to Development phase provides integrated services to both innovator and generic pharma companies. JRF Global’s top management is committed and actively involved in the establishment, management and monitoring of quality systems. This is achieved by documenting quality policies and objectives and ensuring that both are understood and implemented by all scientists’ at all the levels. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cara Therapeutics Enters Commercial License Agreement With Enteris BioPharma

Cara Therapeutics Enters Commercial License Agreement With Enteris BioPharma

Cara Therapeutics, Inc. recently announced it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to…..

Viral Vectors Expected to Play Pivotal Role in Gene Therapy Pipeline for Neurology Indications

Viral Vectors Expected to Play Pivotal Role in Gene Therapy Pipeline for Neurology Indications

Viral vectors, such as adeno-associated virus (AAV), are expected to play a pivotal role in gene therapies for neurology indications, as this vector type has been found to be the most…..

Q BioMed & ChemVeda Announce Potential Chemotherapeutic Breakthrough

Q BioMed & ChemVeda Announce Potential Chemotherapeutic Breakthrough

Q BioMed, Inc. and Chemveda Life Sciences recently announce the successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential………

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Developing ODTs is a worldwide trend. In recent years, new excipients and excipient blends have enabled manufacturers to produce ODTs using conventional equipment, ie, blenders and tablet presses. One such product is GRANFILLER-D………

Creating Your Secondary Packaging Strategy - Begin With the End in Mind

Creating Your Secondary Packaging Strategy - Begin With the End in Mind

Whether it is meeting the needs of a rapidly aging market, blocking drug counterfeiters, or differentiating your pharmaceutical product in the market, a secondary packaging program is an important factor in………

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 4 – Drug Delivery
September 11 – Injection Devices